LGMD-R5 | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

85 results for “LGMD-R5”

Trials

View all 44 →

Defining Clinical Endpoints in Limb Girdle Muscular Dystrophy (LGMD)

116 participants · First posted Jun 10, 2019

Active, not recruiting

LGMD R1 Natural History Study

100 participants · First posted Nov 16, 2022

Not yet recruiting

Evaluating Safety and Efficacy of Autologous Gene-edited Muscle Stem Cells (GenPHSats-bASKet)

6 participants · First posted Oct 20, 2022

Drugs

View all 22 →

APB-R5

Ph-R5

Satgeno-LGMD

Organizations

LGM Pharmaceuticals, Inc.

United States

LGM Pharma Solutions, LLC

United States

News

View all 17 →

Atamyo Therapeutics Reports Promising Early Results for ATA-200 Gene Therapy in Rare Muscular Dystrophy

Atamyo Therapeutics' ATA-200 Gene Therapy Receives FDA Clearance for US Clinical Trial in LGMD2C/R5

Atamyo Therapeutics Advances Gene Therapy Programs for Limb-Girdle Muscular Dystrophy

Page 1 of 9